These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 27157897

  • 1. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
    Baptiste GG, Postlewait LM, Ethun CG, Le N, McInnis MR, Russell MC, Winer JH, Kooby DA, Staley CA, Maithel SK, Cardona K.
    J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
    [Abstract] [Full Text] [Related]

  • 2. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC, Ethun CG, Postlewait LM, Lopez-Aguiar AG, Zhelnin K, Krasinskas A, El-Rayes BF, Russell MC, Kooby DA, Staley CA, Cardona K, Maithel SK.
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
    Watanabe A, Yip L, Hamilton TD, Loree JM, Stuart HC.
    Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, Chen Y, Li Y, Chen M, Zhou Z, Chen J.
    Chin J Cancer; 2017 Jun 21; 36(1):51. PubMed ID: 28637502
    [Abstract] [Full Text] [Related]

  • 6. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
    Keck KJ, Choi A, Maxwell JE, Li G, O'Dorisio TM, Breheny P, Bellizzi AM, Howe JR.
    Ann Surg Oncol; 2017 Aug 21; 24(8):2206-2212. PubMed ID: 28560597
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y, Han X, Xu XF, Ji Y, Zhou YH, Sun HC, Zhou J, Fan J, Lou WH, Huang C.
    BMC Cancer; 2019 Apr 08; 19(1):335. PubMed ID: 30961559
    [Abstract] [Full Text] [Related]

  • 9. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN, Zajac-Kaye M.
    Int J Cancer; 2014 Jul 01; 135(1):128-37. PubMed ID: 24347111
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
    Ozkara S, Aker F, Yesil A, Senates E, Canbey C, Yitik A, Gonen C.
    Hepatogastroenterology; 2013 Oct 01; 60(127):1665-72. PubMed ID: 24627925
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
    Kankava K, Maisonneuve P, Mangogna A, Centonze G, Cattaneo L, Prinzi N, Pusceddu S, Fazio N, Pisa E, Di Domenico S, Bertani E, Mazzaferro V, Albertelli M, Grillo F, Milione M.
    J Neuroendocrinol; 2021 Aug 01; 33(8):e13000. PubMed ID: 34268808
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, Lu CH, Hwang TL.
    Anticancer Res; 2014 Oct 01; 34(10):5661-9. PubMed ID: 25275071
    [Abstract] [Full Text] [Related]

  • 16. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
    Keck KJ, Maxwell JE, Menda Y, Bellizzi A, Dillon J, O'Dorisio TM, Howe JR.
    Surgery; 2017 Jan 01; 161(1):272-279. PubMed ID: 27863780
    [Abstract] [Full Text] [Related]

  • 17. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
    Grillo F, Albertelli M, Annunziata F, Boschetti M, Caff A, Pigozzi S, Ferone D, Mastracci L.
    Endocrine; 2016 Jul 01; 53(1):58-62. PubMed ID: 26362059
    [Abstract] [Full Text] [Related]

  • 18. STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?
    Lopez-Aguiar AG, Postlewait LM, Ethun CG, Zaidi MY, Zhelnin K, Krasinskas A, Russell MC, Kooby DA, Cardona K, El-Rayes BF, Maithel SK.
    J Gastrointest Surg; 2020 May 01; 24(5):1138-1148. PubMed ID: 31144189
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, Su YL, Ku FC, Chou WC, Chen YY.
    Asia Pac J Clin Oncol; 2016 Dec 01; 12(4):396-402. PubMed ID: 27357443
    [Abstract] [Full Text] [Related]

  • 20. Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors.
    Pandrowala SA, Kapoor D, Kunte A, Chopde A, Puranik A, Dev ID, Parghane R, Basu S, Ramaswamy A, Ostwal V, Chaudhari VA, Bhandare MS, Shrikhande SV.
    J Gastrointest Cancer; 2024 Sep 01; 55(3):1220-1228. PubMed ID: 38874852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.